Press Releases Ovid Therapeutics Inc.

Equities

OVID

US6904691010

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
3.05 ^USD	+1.67%		-1.93%	-5.28%

May. 14	Earnings Flash (OVID) OVID THERAPEUTICS Posts Q1 Revenue $148,000	MT
May. 14	Ovid Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results	May. 14	GL
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results	May. 14	AQ
Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference	May. 13	GL
Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference	Apr. 04	GL
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus Post Grant Review	Mar. 28	AQ
Ovid Therapeutics : Corporate Presentation	Mar. 08	PU
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results	Mar. 08	GL
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results	Mar. 08	AQ
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference	Feb. 28	GL
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference	Feb. 28	AQ
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Feb. 06	GL
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Feb. 06	AQ
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting	Dec. 04	AQ
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)	Dec. 01	GL
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)	Dec. 01	AQ
Ovid Therapeutics : Corporate Presentation	Nov. 03	PU
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates	Nov. 03	GL
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026	23-10-19	AQ
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026	23-10-18	GL
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026	23-10-18	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Ovid Therapeutics Inc.

Equities

OVID

US6904691010

Press Releases

Filters